Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Summit Therapeutics

DB:UVF1
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UVF1
DB
$94M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
  • Summit Therapeutics has significant price volatility in the past 3 months.
UVF1 Share Price and Events
7 Day Returns
-11.5%
DB:UVF1
-8.1%
DE Biotechs
-6.8%
DE Market
1 Year Returns
-41.1%
DB:UVF1
2.8%
DE Biotechs
6.5%
DE Market
UVF1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Summit Therapeutics (UVF1) -11.5% -9.9% -6.5% -41.1% - -
DE Biotechs -8.1% -9.4% -4.5% 2.8% 29.9% 4.6%
DE Market -6.8% -3.7% -3.6% 6.5% -2.6% -2.9%
1 Year Return vs Industry and Market
  • UVF1 underperformed the Biotechs industry which returned 2.8% over the past year.
  • UVF1 underperformed the Market in Germany which returned 6.5% over the past year.
Price Volatility
UVF1
Industry
5yr Volatility vs Market

Value

 Is Summit Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Summit Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Summit Therapeutics.

DB:UVF1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:UVF1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.37
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.37 (1 + (1- 19%) (1.04%))
1.255
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.26
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.255 * 6.07%)
7.23%

Discounted Cash Flow Calculation for DB:UVF1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Summit Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:UVF1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 7.23%)
2020 -14.35 Analyst x1 -13.39
2021 -32.36 Analyst x1 -28.15
2022 -42.62 Analyst x1 -34.56
2023 -26.75 Analyst x1 -20.23
2024 1.56 Analyst x1 1.10
2025 15.26 Analyst x1 10.04
2026 25.25 Est @ 65.48% 15.49
2027 36.80 Est @ 45.72% 21.05
2028 48.53 Est @ 31.88% 25.89
2029 59.30 Est @ 22.2% 29.51
Present value of next 10 years cash flows £6.00
DB:UVF1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= £59.30 × (1 + -0.39%) ÷ (7.23% – -0.39%)
£775.21
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £775.21 ÷ (1 + 7.23%)10
£385.71
DB:UVF1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £6.00 + £385.71
£391.71
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £391.71 / 67.23
£5.83
DB:UVF1 Discount to Share Price
Calculation Result
Exchange Rate GBP/USD
(Reporting currency to currency of NasdaqGM:SMMT)
1.287
Value per Share
(USD)
= Value per Share in GBP x Exchange Rate (GBP/USD)
= £5.83 x 1.287
$7.5
Non-primary Listing Adjustment Factor 1 share in DB:UVF1 represents 0.14065x of NasdaqGM:SMMT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.14065x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 7.50 x 0.14065
€1.05
Value per share (EUR) From above. €1.05
Current discount Discount to share price of €0.20
= -1 x (€0.20 - €1.05) / €1.05
81.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Summit Therapeutics is available for.
Intrinsic value
>50%
Share price is €0.2 vs Future cash flow value of €1.05
Current Discount Checks
For Summit Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Summit Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Summit Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Summit Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Summit Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UVF1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-10-31) in GBP £-0.73
NasdaqGM:SMMT Share Price ** NasdaqGM (2020-02-21) in USD $1.39
NasdaqGM:SMMT Share Price converted to GBP reporting currency Exchange rate (USD/ GBP) 0.777 £1.08
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 37.58x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 19.97x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Summit Therapeutics.

DB:UVF1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SMMT Share Price ÷ EPS (both in GBP)

= 1.08 ÷ -0.73

-1.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Summit Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Summit Therapeutics's expected growth come at a high price?
Raw Data
DB:UVF1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
37.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.43x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Summit Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Summit Therapeutics's assets?
Raw Data
DB:UVF1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-10-31) in GBP £0.84
NasdaqGM:SMMT Share Price * NasdaqGM (2020-02-21) in USD $1.39
NasdaqGM:SMMT Share Price converted to GBP reporting currency Exchange rate (USD/ GBP) 0.777 £1.08
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.19x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.77x
DB:UVF1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SMMT Share Price ÷ Book Value per Share (both in GBP)

= 1.08 ÷ 0.84

1.29x

* Primary Listing of Summit Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Summit Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Summit Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Summit Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Summit Therapeutics expected to grow at an attractive rate?
  • Summit Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Summit Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Summit Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:UVF1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UVF1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 37.2%
DB:UVF1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 24.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 35.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UVF1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UVF1 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2025-01-31 52 16 20 1
2024-12-31 27
2024-01-31 35 2 5 1
2023-12-31 15
2023-01-31 -26 -32
2022-12-31 -10
2022-01-31 5 -34 -36 3
2021-12-31 -22
2021-01-31 12 -29 -31 3
2020-12-31 -18
2020-02-27
2020-01-31 15 -14 -21 2
2019-12-31 -19
DB:UVF1 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-10-31 20 -18 -21
2019-07-31 20 -16 -22
2019-04-30 55 -18 9
2019-01-31 58 -27 8
2018-10-31 55 -28 1
2018-07-31 55 -34 9
2018-04-30 20 -14 -21
2018-01-31 14 -15 -20
2017-10-31 12 -15 -14
2017-07-31 9 23 -18
2017-04-30 4 11 -21
2017-01-31 2 12 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Summit Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Summit Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UVF1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Summit Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UVF1 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2025-01-31
2024-12-31 0.08 0.08 0.08 1.00
2024-01-31
2023-12-31 0.05 0.05 0.05 1.00
2023-01-31
2022-12-31 -0.03 -0.03 -0.03 1.00
2022-01-31
2021-12-31 -0.07 -0.07 -0.07 1.00
2021-01-31
2020-12-31 -0.05 -0.05 -0.05 1.00
2020-02-27
2020-01-31
2019-12-31 -0.11 -0.11 -0.11 1.00
DB:UVF1 Past Financials Data
Date (Data in GBP Millions) EPS *
2019-10-31 -0.73
2019-07-31 -0.89
2019-04-30 0.44
2019-01-31 0.44
2018-10-31 0.09
2018-07-31 0.58
2018-04-30 -1.54
2018-01-31 -1.54
2017-10-31 -1.10
2017-07-31 -1.42
2017-04-30 -1.68
2017-01-31 -1.74

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Summit Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Summit Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Summit Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Summit Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Summit Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Summit Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Summit Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Summit Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Summit Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Summit Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UVF1 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-10-31 20.12 -21.34 9.51 34.25
2019-07-31 19.56 -22.45 9.79 35.22
2019-04-30 55.50 9.34 10.92 35.86
2019-01-31 57.62 7.53 11.59 39.17
2018-10-31 54.70 1.37 14.41 39.54
2018-07-31 55.13 8.64 11.73 38.77
2018-04-30 19.61 -21.27 11.89 35.53
2018-01-31 14.17 -20.19 12.00 28.97
2017-10-31 11.51 -13.83 9.93 23.86
2017-07-31 8.78 -17.55 9.86 20.39
2017-04-30 4.05 -20.70 9.28 19.18
2017-01-31 2.38 -21.37 8.28 18.95
2016-10-31 0.87 -23.57 6.64 19.16
2016-07-31 0.52 -24.60 6.04 19.70
2016-04-30 0.93 -22.21 5.13 18.53
2016-01-31 1.28 -20.14 4.77 16.86
2015-10-31 1.60 -16.03 4.69 14.63
2015-07-31 1.84 -12.86 4.02 12.73
2015-04-30 1.92 -12.11 4.62 10.99
2015-01-31 1.89 -11.38 3.70 10.42
2014-10-31 2.07 -10.63 3.76 9.89
2014-07-31 2.48 -9.86 3.59 9.57
2014-04-30 2.23 -7.65 2.42 8.13
2014-01-31 1.84 -6.09 1.94 6.61
2013-10-31 -0.03 -4.81 1.79 5.51
2013-07-31 1.30 -4.13 1.82 3.85
2013-04-30 1.56 -4.18 1.79 3.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Summit Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Summit Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Summit Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Summit Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Summit Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Summit Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Summit Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Summit Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Summit Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Summit Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Summit Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Summit Therapeutics Company Filings, last reported 3 months ago.

DB:UVF1 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-10-31 26.86 0.00 13.60
2019-07-31 33.71 0.00 20.87
2019-04-30 38.64 0.00 28.32
2019-01-31 42.54 0.00 26.86
2018-10-31 28.03 0.00 13.04
2018-07-31 33.05 0.00 17.13
2018-04-30 5.77 0.00 27.69
2018-01-31 -3.18 0.00 20.10
2017-10-31 16.10 0.00 31.81
2017-07-31 3.50 0.00 28.29
2017-04-30 -7.98 0.00 19.36
2017-01-31 -3.49 0.00 28.06
2016-10-31 1.09 0.00 34.63
2016-07-31 10.57 0.00 7.00
2016-04-30 16.33 0.00 9.99
2016-01-31 16.08 0.00 16.30
2015-10-31 25.91 0.00 22.19
2015-07-31 30.22 0.00 26.44
2015-04-30 33.87 0.00 29.41
2015-01-31 12.96 0.00 11.27
2014-10-31 17.66 0.00 15.01
2014-07-31 20.00 0.00 17.44
2014-04-30 4.76 0.00 2.03
2014-01-31 4.76 0.00 2.03
2013-10-31
2013-07-31 5.25 0.00 6.00
2013-04-30 5.25 0.00 6.00
  • Summit Therapeutics has no debt.
  • Summit Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Summit Therapeutics has less than a year of cash runway based on current free cash flow.
  • Summit Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.2% each year.
X
Financial health checks
We assess Summit Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Summit Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Summit Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Summit Therapeutics dividends.
If you bought €2,000 of Summit Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Summit Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Summit Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UVF1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 2.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.7%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UVF1 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2025-01-31
2024-12-31
2024-01-31
2023-12-31
2023-01-31
2022-12-31
2022-01-31
2021-12-31
2021-01-31
2020-12-31
2020-02-27
2020-01-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Summit Therapeutics has not reported any payouts.
  • Unable to verify if Summit Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Summit Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Summit Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Summit Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Summit Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Summit Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Summit Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Glyn Edwards
COMPENSATION £650,279
AGE 63
TENURE AS CEO 7.8 years
CEO Bio

Mr. Glyn O. Edwards, MBE, serves as Chief Executive Officer and Executive Director of Summit Therapeutics plc since April 4, 2012 and served as its Chairman since December 24, 2019 until February 26, 2020. Mr. Edwards has a wealth of expertise garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles. He served as the Chief Executive Officer of Antisoma plc since March 1998 and served as its Executive Director since March 16, 1998 until February 28, 2011. Prior to joining Antisoma, he served as the Vice President of Business Development at Therapeutic Antibodies Inc. since January 1998. He has worked with Celltech PLC and 3M United Kingdom PLC. Mr. Edwards was the Founder of Oros Instruments Limited. From 1995 to 1998, he served as a Consultant of TAb through Elara Associates Limited. Mr. Edwards served as the Chairman of Executive Board and Member of Executive Board at Antisoma Research Limited. He serves as an Executive Director at Xanthus Pharmaceuticals, Inc. He serves as a Director of Elara Associates Limited, Cancer Therapeutics Limited. Mr. Edwards is a Member of Review Panel of Heptagon Fund. He holds a BS degree in Biochemistry from Bristol University and an MS degree in Economics from London Business School.

CEO Compensation
  • Glyn's compensation has increased whilst company is loss making.
  • Glyn's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Summit Therapeutics management team in years:

4.4
Average Tenure
55
Average Age
  • The tenure for the Summit Therapeutics management team is about average.
Management Team

Glyn Edwards

TITLE
CEO & Executive Director
COMPENSATION
£650K
AGE
63
TENURE
7.8 yrs

Kay Davies

TITLE
Co-Founder
AGE
69

Melissa Strange

TITLE
VP of Finance & Company Secretary
AGE
39
TENURE
1.2 yrs

Dave Powell

TITLE
Senior VP & Head of Research
AGE
50

Richard Vickers

TITLE
Chief Scientific Officer & Senior VP of Research and Development?
AGE
43

Michelle Avery

TITLE
Director of Investor Relations
TENURE
4.4 yrs

Richard Pye

TITLE
Senior Director of Corporate Affairs & Communications

Anna Triola

TITLE
Vice President of Marketing

Jonathon Tinsley

TITLE
Chief Scientific Officer of DMD
AGE
60
TENURE
6.3 yrs

Anne Heatherington

TITLE
Head of Clinical Development and Quantitative Sciences
TENURE
2.8 yrs
Board of Directors

Kay Davies

TITLE
Co-Founder
AGE
69

Marcel van den Heuvel

TITLE
Member of Scientific Advisory Board

Glyn Edwards

TITLE
CEO & Executive Director
COMPENSATION
£650K
AGE
63
TENURE
7.8 yrs

Francesco Muntoni

TITLE
Member of Scientific Advisory Board

Roger Patient

TITLE
Member of Scientific Advisory Board

Edith Sim

TITLE
Member of Scientific Advisory board

Bob Sim

TITLE
Member of Scientific Advisory board

Derek Stemple

TITLE
Member of Scientific Advisory board

Jean-Paul Vincent

TITLE
Member of Scientific Advisory board

William Richards

TITLE
Member of Scientific Advisory board
AGE
79
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Summit Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Jan 20 Buy Shaun Zanganeh Irrevocable Trust Company 14. Jan 20 14. Jan 20 10,522,705 €0.26 €2,718,174
23. Jan 20 Buy Mahkam Zanganeh Individual 14. Jan 20 14. Jan 20 10,522,705 €0.26 €2,718,174
16. Jan 20 Sell Robert Duggan Individual 14. Jan 20 14. Jan 20 -33,321,870 €0.26 €-8,607,542
27. Dec 19 Buy Robert Duggan Individual 24. Dec 19 24. Dec 19 166,157,050 €0.26 €42,924,705
X
Management checks
We assess Summit Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Summit Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-571, a preclinical stage candidate to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Details
Name: Summit Therapeutics plc
UVF1
Exchange: DB
Founded: 2003
$86,063,255
67,231,902
Website: http://www.summitplc.com
Address: Summit Therapeutics plc
136a Eastern Avenue,
Milton Park,
Abingdon,
Oxfordshire, OX14 4SB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SMMT SPONS ADS Nasdaq Global Market US USD 06. Mar 2015
DB UVF1 Ordinary Shares Deutsche Boerse AG DE EUR 14. Oct 2004
Number of employees
Current staff
Staff numbers
61
Summit Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/27 23:30
End of day share price update: 2020/02/21 00:00
Last estimates confirmation: 2020/02/13
Last earnings filing: 2019/12/17
Last earnings reported: 2019/10/31
Last annual earnings reported: 2019/01/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.